AstraZeneca's Imfinzi/Tremelimumab Combo Conquers HIMALAYA
Improves Overall Survival In Liver Cancer Patients
After the combination's success in the non-small cell lung cancer POSEIDON study, AstraZeneca's Imfinzi and tremelimumab could now be on the way to approval as a first-line treatment for hepatocellular carcinoma.
You may also be interested in...
AstraZeneca is one of the sector’s top growth stories in 2021, but controversies around its COVID-19 vaccine continue to grab headlines, and Chinese price cuts bite.
The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.